OrthodontiCell Secures Capital to Complete Testing Supporting Planned U.S. Phase II Pivotal Study
OrthodontiCell, Inc. announced today it believes it has secured sufficient capital to complete all FDA requested tests to file an application to request permission to begin a planned Phase II multi-center Pivotal Clinical Study in the USA for its bioelectric protein expression platform technology for accelerating teeth straightening OrthodontiCel
Salt Lake City, Utah (Newsworthy.ai) Thursday Oct 15, 2026 @ 3:00 AM PDT
OrthodontiCell TM Bioelectric Protein Expression System for Accelerating Teeth Straightening
Photo: OrthondontiCell, Inc.
“For patients and families, a shorter path to a healthy, confident smile can make a meaningful difference,” said Mark Terrill CEO. “Securing the capital to complete this testing moves OrthodontiCell closer to its next clinical milestone and gives our team the resources to advance the application process.”
OrthodontiCell, Inc. announced today that it has secured sufficient capital to complete the remaining testing needed to support its application to begin a planned Phase II pivotal clinical study in the United States.
The funding marks a significant milestone in the company’s development of bioelectric technology designed to accelerate tooth movement during orthodontic treatment. OrthodontiCell’s approach aims to shorten treatment time and improve the patient experience when used alongside orthodontic care.
OrthodontiCell TM Bioelectric Protein Expression System for Accelerating Teeth Straightening
Photo: OrthondontiCell, Inc.
“For patients and families, a shorter path to a healthy, confident smile can make a meaningful difference,” said Mark Terrill CEO. “Securing the capital to complete this testing moves OrthodontiCell closer to its next clinical milestone and gives our team the resources to advance the application process.”
With funding in place for this stage, the company can now focus on completing the testing and prepare its regulatory submission seeking authorization to initiate the planned final pivotal U.S. study.
The proposed study is intended to evaluate the technology’s safety and effectiveness, including its potential to reduce the time required to straighten teeth. Final study design, participating centers, and enrollment timing will be announced in the near future, as the program advances.
“For patients and families, a shorter path to a healthy, confident smile can make a meaningful difference,” said Mark Terrill CEO. “Securing the capital to complete this testing moves OrthodontiCell closer to its next clinical milestone and gives our team the resources to advance the application process.”
The capital secured covers the remaining testing supporting the planned application. Funding for conducting the pivotal study will be addressed separately.
About OrthodontiCell
OrthodontiCell, Inc. is developing bioelectric technology intended to accelerate orthodontic tooth movement and improve the treatment experience. Its development program focuses on evaluating the use of controlled bioelectric stimulation alongside orthodontic treatment.
Development Status and Forward-Looking Statements
OrthodontiCell’s technology remains investigational. Initiation of the planned U.S. study is subject to completion of testing and applicable regulatory and ethics approvals. Statements concerning development plans, treatment benefits, and future milestones reflect current expectations; actual results and timing may differ.
